Tamoxifen
Information
- Drug Name
- Tamoxifen
- Description
- Entry(CIViC)
- 15
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00066690 | Active, not recruiting | Phase 3 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | December 17, 2003 | December 2025 |
| NCT02668666 | Active, not recruiting | Phase 2 | Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer | June 30, 2016 | November 2023 |
| NCT04961632 | Active, not recruiting | Phase 1 | Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376 | December 23, 2020 | November 2025 |
| NCT02228681 | Active, not recruiting | Phase 2 | Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | May 21, 2015 | |
| NCT00066703 | Active, not recruiting | Phase 3 | Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | November 3, 2003 | December 2025 |
| NCT05035836 | Active, not recruiting | Phase 2 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | November 16, 2021 | December 29, 2024 |
| NCT04300790 | Active, not recruiting | Phase 2 | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | October 23, 2020 | June 30, 2026 |
| NCT05501158 | Active, not recruiting | N/A | CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population | January 1, 2021 | June 30, 2024 |
| NCT00412022 | Active, not recruiting | Phase 3 | HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | March 2004 | November 2024 |
| NCT02764541 | Active, not recruiting | Phase 2 | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | May 24, 2016 | April 2031 |
| NCT04059484 | Active, not recruiting | Phase 2 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | October 22, 2019 | September 30, 2024 |
| NCT03423199 | Active, not recruiting | Phase 3 | PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | February 9, 2018 | September 2025 |
| NCT03280563 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | December 26, 2017 | December 31, 2024 |
| NCT01357772 | Active, not recruiting | Phase 3 | Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up | November 12, 2008 | December 31, 2028 |
| NCT03219476 | Active, not recruiting | Phase 2 | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | February 5, 2017 | July 1, 2024 |
| NCT01579734 | Active, not recruiting | Phase 3 | Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users | March 2002 | December 2023 |
| NCT03554044 | Active, not recruiting | Phase 1 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | February 5, 2020 | April 30, 2025 |
| NCT03161353 | Active, not recruiting | Phase 2 | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | June 26, 2017 | November 1, 2026 |
| NCT02206984 | Active, not recruiting | Phase 2 | Endocrine Response in Women With Invasive Lobular Breast Cancer | September 30, 2015 | July 31, 2024 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT02747004 | Active, not recruiting | Phase 2 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer | September 14, 2016 | December 30, 2024 |
| NCT00291759 | Completed | Phase 3 | ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation. | January 1996 | June 2009 |
| NCT00293540 | Completed | Phase 3 | Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | February 2006 | March 2015 |
| NCT00295100 | Completed | Phase 2 | Tamoxifen-MRI Study | September 2000 | July 2006 |
| NCT00295646 | Completed | Phase 3 | Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | June 1999 | June 26, 2018 |
| NCT00309478 | Completed | Phase 3 | Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | December 1990 | June 2004 |
| NCT00375622 | Completed | Phase 2 | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial | February 2005 | June 2006 |
| NCT00433589 | Completed | Phase 3 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | February 2007 | March 2020 |
| NCT00537771 | Completed | Phase 4 | Liver Safety Under Upfront Arimidex vs Tamoxifen | September 2007 | December 2011 |
| NCT00590785 | Completed | Phase 3 | Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | August 13, 1996 | January 13, 2015 |
| NCT00605267 | Completed | Phase 3 | Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment | October 2007 | December 2010 |
| NCT00637871 | Completed | Phase 2 | Casodex - Nolvadex Combination | November 2002 | August 2005 |
| NCT00659373 | Completed | Phase 3 | Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 | December 2007 | April 2016 |
| NCT00000529 | Completed | Phase 3 | Tamoxifen Study | May 1992 | November 1995 |
| NCT00710970 | Completed | Phase 2 | Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment | January 2007 | December 2012 |
| NCT00728949 | Completed | Phase 2 | A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | August 2008 | February 2015 |
| NCT00749138 | Completed | Phase 1 | Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy | November 2008 | October 2009 |
| NCT00784680 | Completed | Phase 3 | ATAC - Quality of Life Sub-Protocol | April 1998 | April 2004 |
| NCT00784862 | Completed | Phase 3 | ATAC - Pharmacokinetics (PK) Sub-Protocol | June 1998 | March 1999 |
| NCT00784940 | Completed | Phase 3 | ATAC - Bone Density Sub-Protocol | June 1998 | April 2007 |
| NCT00827307 | Completed | N/A | Zoladex Plus Tamoxifen in Breast Cancer | June 2008 | August 2011 |
| NCT00847366 | Completed | N/A | Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma | May 2008 | December 2012 |
| NCT00900744 | Completed | A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 | January 2009 | January 2012 | |
| NCT00919399 | Completed | Phase 2 | Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | January 2002 | June 2006 |
| NCT00999921 | Completed | Phase 4 | Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer | January 2008 | January 2015 |
| NCT01027416 | Completed | N/A | Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients | December 14, 2009 | December 2015 |
| NCT01075802 | Completed | N/A | Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms | March 2010 | December 2012 |
| NCT01124695 | Completed | Phase 2 | Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer | January 7, 2011 | December 2022 |
| NCT01169792 | Completed | Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients | |||
| NCT01189500 | Completed | Phase 4 | Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects | August 2010 | October 2010 |
| NCT01220076 | Completed | Phase 2 | Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+ | September 2009 | October 2016 |
| NCT01257581 | Completed | Phase 2 | Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | March 2011 | February 2013 |
| NCT01298713 | Completed | Phase 2 | Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer | March 2008 | September 12, 2018 |
| NCT01393990 | Completed | Phase 1 | A Study of LY2228820 in Participants With Advanced Cancer | September 4, 2008 | December 14, 2013 |
| NCT01614210 | Completed | Phase 2 | Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance | August 2012 | November 2016 |
| NCT01638247 | Completed | Phase 3 | Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients | August 2012 | May 2018 |
| NCT01896050 | Completed | Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer | September 2009 | August 2014 | |
| NCT00687102 | Completed | Phase 3 | Cognition in the Study of Tamoxifen and Raloxifene | October 2001 | March 2008 |
| NCT00001436 | Completed | Phase 1 | A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma | May 1995 | September 2000 |
| NCT00002707 | Completed | Phase 3 | Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed | December 1995 | February 2010 |
| NCT00003906 | Completed | Phase 3 | Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women | May 1999 | August 2012 |
| NCT00005822 | Completed | Phase 1 | SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer | April 2000 | October 2003 |
| NCT00026585 | Completed | Phase 2 | Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder | November 9, 2001 | November 2, 2007 |
| NCT00031720 | Completed | Phase 2 | Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease | March 2002 | November 2013 |
| NCT00034125 | Completed | Phase 3 | Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer. | ||
| NCT00038467 | Completed | Phase 3 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | February 1998 | March 2013 |
| NCT00165308 | Completed | N/A | Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors | April 2001 | June 2009 |
| NCT00171704 | Completed | Phase 3 | A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | April 2005 | March 2011 |
| NCT00189358 | Completed | Phase 2 | A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy | ||
| NCT00201851 | Completed | Phase 3 | Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer | January 2004 | May 2013 |
| NCT00206544 | Completed | Phase 2 | Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? | January 2004 | December 2007 |
| NCT00214110 | Completed | Phase 2 | Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] | January 2001 | January 2005 |
| NCT00229697 | Completed | Phase 2 | Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study | October 2003 | June 2015 |
| NCT00233610 | Completed | Phase 3 | Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer | December 2003 | October 2007 |
| NCT00241449 | Completed | Phase 3 | A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer | November 1998 | January 2012 |
| NCT00279448 | Completed | Phase 3 | Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer | January 2002 | June 2009 |
| NCT00286117 | Completed | Phase 3 | ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years | March 1998 | May 2006 |
| NCT00287534 | Completed | Phase 2 | Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women. | November 1996 | September 2004 |
| NCT02070692 | Completed | Phase 4 | Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users | February 2014 | December 2015 |
| NCT02093351 | Completed | Phase 1 | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | September 1, 2014 | April 29, 2019 |
| NCT02278120 | Completed | Phase 3 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | November 20, 2014 | April 20, 2023 |
| NCT02285179 | Completed | Phase 1/Phase 2 | Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen | November 2014 | May 1, 2022 |
| NCT02291913 | Completed | Phase 2 | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | December 18, 2014 | January 31, 2019 |
| NCT02333370 | Completed | Phase 1 | A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | February 4, 2015 | September 29, 2022 |
| NCT02344940 | Completed | Phase 4 | Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | December 2014 | August 2018 |
| NCT02384239 | Completed | Phase 2 | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | October 19, 2015 | January 31, 2021 |
| NCT02404844 | Completed | Phase 2 | Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | December 2014 | October 19, 2017 |
| NCT02479256 | Completed | Phase 4 | Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs | June 2015 | May 2016 |
| NCT02584465 | Completed | Phase 2 | REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression | August 28, 2015 | September 19, 2021 |
| NCT02586675 | Completed | Phase 1 | TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | February 23, 2016 | October 27, 2021 |
| NCT02728622 | Completed | Phase 3 | Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane | March 2002 | January 2009 |
| NCT02806544 | Completed | Phase 2 | Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country | January 2013 | September 2014 |
| NCT02824224 | Completed | Phase 4 | Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) | September 6, 2016 | January 8, 2018 |
| NCT02835079 | Completed | Phase 1 | Treatment Effect of Tamoxifen on Patients With DMD | November 2016 | November 2020 |
| NCT02866955 | Completed | Phase 2 | Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor. | June 15, 2011 | August 28, 2015 |
| NCT02903121 | Completed | Phase 4 | Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users | January 20, 2017 | June 5, 2019 |
| NCT02970682 | Completed | Phase 2 | SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer | October 2016 | March 2019 |
| NCT02979301 | Completed | N/A | Impact of Low-dose Tamoxifen on BPU | March 1, 2017 | November 1, 2018 |
| NCT02988986 | Completed | Phase 2 | TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer | April 24, 2017 | March 30, 2019 |
| NCT02995772 | Completed | Phase 3 | Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients | November 2011 | November 2018 |
| NCT03112031 | Completed | Phase 2 | Treatment With Tamoxifen in Cryptococcal Meningitis | October 10, 2017 | July 17, 2018 |
| NCT03272477 | Completed | Phase 2 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | October 5, 2017 | March 4, 2024 |
| NCT03354039 | Completed | Phase 3 | Tamoxifen in Duchenne Muscular Dystrophy | June 12, 2018 | October 18, 2022 |
| NCT03382834 | Completed | Phase 2 | Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors | April 26, 2018 | July 27, 2023 |
| NCT03528902 | Completed | Phase 2 | Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension | October 1, 2018 | June 14, 2023 |
| NCT03691493 | Completed | Phase 2 | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | February 8, 2019 | October 13, 2022 |
| NCT03715413 | Completed | Phase 2 | Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia | August 15, 2018 | December 1, 2018 |
| NCT03870399 | Completed | Phase 2 | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | March 13, 2019 | May 13, 2023 |
| NCT04079517 | Completed | Phase 1/Phase 2 | Karolinska Interventional Study of Mammograhic Density (Karisma-1) | March 2015 | March 2016 |
| NCT05378269 | Completed | Phase 1/Phase 2 | Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA | November 22, 2021 | March 1, 2023 |
| NCT05645536 | Enrolling by invitation | Phase 3 | Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | December 28, 2022 | June 2028 |
| NCT06348134 | Not yet recruiting | Phase 2 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | July 1, 2024 | July 1, 2036 |
| NCT05801705 | Not yet recruiting | Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | June 1, 2023 | December 30, 2023 | |
| NCT06346457 | Not yet recruiting | Breast Cancer & Antiestrogenic Therapy & Brain | April 1, 2024 | April 1, 2026 | |
| NCT06223698 | Not yet recruiting | Phase 3 | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer | May 2, 2024 | May 2, 2035 |
| NCT06195306 | Not yet recruiting | Phase 2 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | June 16, 2024 | January 1, 2027 |
| NCT06184750 | Not yet recruiting | Phase 2 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | November 26, 2024 | July 1, 2028 |
| NCT06440967 | Not yet recruiting | Phase 3 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | June 30, 2024 | August 31, 2027 |
| NCT06179303 | Not yet recruiting | Phase 2 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | July 6, 2024 | June 1, 2026 |
| NCT05941520 | Not yet recruiting | Phase 2 | Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer | October 8, 2024 | September 1, 2028 |
| NCT06434064 | Not yet recruiting | Phase 2 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | June 30, 2024 | June 30, 2028 |
| NCT05131893 | Not yet recruiting | Neoadjuvant Treatment of Breast Cancer | March 2022 | December 2031 | |
| NCT05156892 | Recruiting | Phase 1 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer | September 4, 2022 | January 1, 2025 |
| NCT05659563 | Recruiting | Phase 2 | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% | July 20, 2023 | December 2024 |
| NCT05774951 | Recruiting | Phase 3 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | March 31, 2023 | May 29, 2036 |
| NCT02914158 | Recruiting | Phase 3 | Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | March 30, 2016 | December 2025 |
| NCT05891093 | Recruiting | Phase 3 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | June 1, 2023 | May 31, 2031 |
| NCT05952557 | Recruiting | Phase 3 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | October 5, 2023 | May 6, 2037 |
| NCT03011684 | Recruiting | Phase 3 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | July 21, 2016 | January 31, 2025 |
| NCT06001762 | Recruiting | Phase 2 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | October 5, 2023 | January 1, 2027 |
| NCT06075953 | Recruiting | Phase 2 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | February 14, 2024 | November 2033 |
| NCT03351062 | Recruiting | Phase 3 | Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | November 2017 | December 2025 |
| NCT03879577 | Recruiting | Phase 2 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | November 25, 2019 | April 10, 2024 |
| NCT04174352 | Recruiting | Early Phase 1 | FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer | October 20, 2020 | December 2025 |
| NCT04570956 | Recruiting | Phase 2 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ | July 26, 2021 | December 31, 2026 |
| NCT04765098 | Recruiting | Phase 2 | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | January 28, 2022 | December 2026 |
| NCT04906395 | Recruiting | Phase 3 | Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | July 1, 2021 | April 30, 2025 |
| NCT04985266 | Recruiting | Phase 2 | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | March 30, 2022 | September 1, 2030 |
| NCT02062489 | Recruiting | Phase 3 | Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients | May 2014 | May 2026 |
| NCT05101564 | Recruiting | Phase 2 | Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | March 20, 2023 | December 2026 |
| NCT05150652 | Recruiting | Phase 2 | Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer | February 18, 2022 | October 2036 |
| NCT05525481 | Recruiting | Phase 4 | Tamoxifen Prediction Study in Patients With ER+ Breast Cancer | November 1, 2022 | February 28, 2024 |
| NCT05161195 | Recruiting | Phase 4 | Roll-over Study to Allow Continued Access to Ribociclib | July 7, 2022 | March 26, 2030 |
| NCT05306340 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | August 3, 2022 | March 31, 2026 |
| NCT02476786 | Recruiting | Phase 2 | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | January 17, 2017 | January 31, 2030 |
| NCT05501704 | Recruiting | Phase 2 | ETHAN - ET for Male BC | October 11, 2023 | April 1, 2036 |
| NCT05512364 | Recruiting | Phase 3 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | December 15, 2023 | May 1, 2030 |
| NCT05514054 | Recruiting | Phase 3 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | October 4, 2022 | March 15, 2032 |
| NCT00738777 | Suspended | Phase 2 | Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer | July 2008 | June 2024 |
| NCT04504331 | Terminated | Phase 1 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | October 13, 2020 | October 22, 2021 |
| NCT00183963 | Terminated | Phase 2 | A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) | August 2006 | June 2008 |
| NCT02089386 | Terminated | Early Phase 1 | Tamoxifen to Treat Barrett's Metaplasia | July 9, 2014 | June 21, 2016 |
| NCT00066807 | Terminated | Phase 3 | Premenopausal Endocrine Responsive Chemotherapy Trial | August 2003 | December 2006 |
| NCT01685255 | Terminated | Phase 2 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | August 2012 | October 23, 2014 |
| NCT05128773 | Terminated | Phase 3 | Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity | February 17, 2022 | October 13, 2022 |
| NCT02936206 | Terminated | Phase 1 | Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | October 2016 | May 1, 2020 |
| NCT02322853 | Terminated | Phase 2 | A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors | January 2015 | April 2017 |
| NCT02395627 | Terminated | Phase 2 | Reversing Therapy Resistance With Epigenetic-Immune Modification | May 4, 2015 | June 8, 2019 |
| NCT00532454 | Terminated | Phase 2 | Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen | June 2006 | December 2007 |
| NCT00290654 | Terminated | Phase 2 | Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ | December 2002 | March 2013 |
| NCT00210028 | Terminated | Phase 2 | Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer | August 2003 | August 2008 |
| NCT04190056 | Terminated | Phase 2 | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | March 11, 2021 | June 15, 2023 |
| NCT00206492 | Terminated | Phase 2 | Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | July 2003 | October 2006 |
| NCT00538330 | Unknown status | N/A | Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer | September 2007 | September 2020 |
| NCT02097459 | Unknown status | Phase 3 | Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer | March 2014 | |
| NCT00973037 | Unknown status | CYP2D6 Genotype on the Clinical Effect of Tamoxifen | March 2009 | April 2016 | |
| NCT03137368 | Unknown status | Phase 3 | A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） | August 9, 2018 | October 30, 2023 |
| NCT03060304 | Unknown status | Phase 4 | The Effect of Tamoxifen on Clinical Outcome in Women With Thin Endometrium Undergoing Frozen Thawed Cycle. | March 2017 | June 2020 |
| NCT02801786 | Unknown status | Phase 2/Phase 3 | TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography | November 2018 | June 2021 |
| NCT00896155 | Unknown status | Phase 3 | Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients | December 2008 | December 2013 |
| NCT00912548 | Unknown status | Phase 3 | Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women | May 2009 | December 2015 |
| NCT02690870 | Unknown status | Phase 4 | Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF | January 2017 | March 2019 |
| NCT04389424 | Unknown status | Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer | September 1, 2017 | January 30, 2022 | |
| NCT00449514 | Unknown status | N/A | Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle | May 2007 | |
| NCT03373708 | Unknown status | Phase 2/Phase 3 | Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | December 20, 2017 | December 20, 2019 |
| NCT04666805 | Unknown status | Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast | July 1, 2020 | January 15, 2021 | |
| NCT02913430 | Unknown status | Early Phase 1 | Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | April 24, 2018 | October 28, 2021 |
| NCT04852081 | Unknown status | Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | January 1, 2021 | December 1, 2021 | |
| NCT02482740 | Unknown status | Phase 2 | A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix | May 2015 | June 2017 |
| NCT00440349 | Unknown status | Phase 2 | Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis | October 2000 | April 2007 |
| NCT02488603 | Unknown status | N/A | Decision Aids for Tamoxifen Treatment in Breast Cancer Patients | August 2015 | |
| NCT01758146 | Unknown status | Phase 3 | Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors | January 2012 | June 2020 |
| NCT02513849 | Unknown status | Phase 1 | Tamoxifen in Patients With Oesophageal Cancer | December 2015 | November 2018 |
| NCT05016349 | Unknown status | Phase 3 | Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. | August 2021 | December 2021 |
| NCT03211572 | Unknown status | Phase 2 | The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers | August 2017 | August 2018 |
| NCT02467686 | Unknown status | Phase 4 | Breast Cancer, Sexuality and Black Cohosh | January 2014 | December 2017 |
| NCT00053339 | Withdrawn | Phase 3 | Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer | ||
| NCT03058939 | Withdrawn | Phase 2 | Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | November 2018 | June 2019 |